Trial Profile

A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Tazemetostat (Primary)
Indications Bladder cancer; Carcinoma; Ureteral neoplasms; Urogenital cancer
Focus Adverse reactions

Most Recent Events

27 Jun 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
27 Jun 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2025.
04 Jun 2024 Results (n=25) assessing the safety and efficacy of tazemetostat and pembrolizumab in advanced urothelial carcinoma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com